An international review has warned that treatment for brain tuberculosis (TB) may be falling short because several commonly used tuberculosis drugs fail to reach the brain and spinal fluid in sufficient amounts. The review, led by Professor Ravindra Kumar Garg, former head of neurology at King George's Medical University in Lucknow, highlighted major gaps in diagnosis and treatment that could affect patient survival.
Critical Findings on Tuberculous Meningitis
"Tuberculous meningitis remains the most severe form of TB. Early diagnosis and medicines that effectively reach the brain are critical," Professor Garg said. The study, published in the journal Expert Review of Anti-infective Therapy, analyzed international clinical trials, World Health Organization guidelines, and studies from multiple countries up to July 2025.
Researchers indicated that doctors may need to administer higher doses of some TB medicines, use drugs with better brain penetration, and employ faster tests for early detection. The review also found that several drug-resistant TB medicines that are effective against lung TB work poorly in brain TB.
Mechanisms and Diagnostic Challenges
The paper explained that TB bacteria can spread through the bloodstream to the brain, causing inflammation and damage to blood vessels. This can lead to stroke, seizures, paralysis, hydrocephalus, vision loss, and coma. Diagnosis is often delayed because early symptoms — including headache, fever, vomiting, and weakness — resemble common illnesses. Routine spinal fluid tests also miss many cases because bacterial levels remain very low.
The review discussed newer diagnostic tools, including GeneXpert Ultra, nanopore sequencing, and metagenomic sequencing, which can detect TB bacteria and drug resistance faster than conventional methods.
Key Finding on Rifampicin
One key finding related to rifampicin, a cornerstone anti-TB drug that cannot pass the blood-brain barrier. Studies from Indonesia and Uganda showed that standard doses often fail to achieve adequate levels in the brain, while higher doses improved survival in some patients.
The review recommended greater use of drugs with better brain penetration, especially for drug-resistant brain TB.
